
News|Articles|May 2, 2004
- Pharmaceutical Technology-05-02-2004
- Volume 28
- Issue 5
aaiPharma Situation Underscores The Need for Due Diligence
Author(s)Jim Miller
Sponsors who have been lax in performing financial due diligence on their contractors have been given a wake-up call by the recent developments at aaiPharma.
Advertisement
Articles in this issue
over 22 years ago
In The Spotlight-May 2004over 22 years ago
FDA Eyes Manufacturing Innovation to Boost Drug Developmentover 22 years ago
Prepare for Bar Codingover 22 years ago
Excipient Functionalityover 22 years ago
May 2004Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What Does Overton's FDA Nomination Mean for Drug Reviews?
2
Q&A: Why Sponsors Are Turning to Mixed FSP/FSO Models
3
PharmTech Explained: China's Biotech Rise Signals New Risks for US Manufacturers
4
Ecopipam's D1 Receptor Approach Signals New Pediatric Neuroscience Pathway
5




